for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Medtronic PLC

MDT.N

Latest Trade

100.95USD

Change

-1.14(-1.12%)

Volume

315,711

Today's Range

100.39

 - 

101.86

52 Week Range

72.16

 - 

122.06

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Medtronic To Acquire Smart Insulin Pen Company Companion Medical

Aug 11 (Reuters) - Medtronic PLC <MDT.N>::MEDTRONIC TO ACQUIRE SMART INSULIN PEN COMPANY COMPANION MEDICAL.MEDTRONIC PLC - TRANSACTION IS EXPECTED TO BE NEUTRAL TO MEDTRONIC'S ADJUSTED EARNINGS PER SHARE IN CURRENT FISCAL YEAR, AND ACCRETIVE THEREAFTER.MEDTRONIC PLC - ADDITIONAL TERMS OF TRANSACTION WERE NOT DISCLOSED..MEDTRONIC PLC - DEAL EXPECTED TO MEET MEDTRONIC'S LONG-TERM FINANCIAL METRICS FOR ACQUISITIONS.

Medtronic To Acquire Medicrea

July 15 (Reuters) - Medtronic PLC <MDT.N>::MEDTRONIC TO ACQUIRE MEDICREA.FRIENDLY VOLUNTARY ALL-CASH TENDER OFFER WILL BE AT A PRICE OF €7.00 PER MEDICREA SHARE.TENDER OFFER WILL TARGET ALL OUTSTANDING SHARES OF MEDICREA AS WELL AS SHARES TO BE ISSUED UPON EXERCISE OF WARRANTS SUBJECT TO THEIR EXERCISE PRIOR TO CLOSING OF TENDER OFFER.COMPLETION OF TENDER OFFER SUBJECT TO MINIMUM ACCEPTANCE CONDITION THAT MEDTRONIC OBTAINS NUMBER OF MEDICREA SHARES REPRESENTING AT LEAST 66.67% OF THE SHARE CAPITAL.ACQUISITION EXPECTED TO CLOSE BY THE END OF CALENDAR YEAR 2020.TRANSACTION EXPECTED TO BE IMMATERIAL TO MEDTRONIC’S ADJUSTED EARNINGS PER SHARE IN FIRST TWO FISCAL YEARS BEFORE TURNING ACCRETIVE IN FISCAL YEAR 2023.

Medtronic And Tandem Diabetes Care Enter Into Patent Cross-License Agreement

July 9 (Reuters) - Tandem Diabetes Care Inc <TNDM.O>::MEDTRONIC AND TANDEM DIABETES CARE ENTER INTO PATENT CROSS-LICENSE AGREEMENT.TANDEM DIABETES CARE INC - NO PAYMENTS WILL BE EXCHANGED AS PART OF THIS AGREEMENT AND FURTHER TERMS WERE NOT DISCLOSED.

ABRE Study Meets Primary Safety And Effectiveness Endpoints

June 16 (Reuters) - Medtronic PLC <MDT.N>::ABRE STUDY MEETS PRIMARY SAFETY AND EFFECTIVENESS ENDPOINTS.MEDTRONIC SELF-EXPANDING VENOUS STENT DEMONSTRATES FAVORABLE OUTCOMES IN PATIENTS WITH VENOUS OUTFLOW OBSTRUCTION.STUDY MET ITS PRIMARY SAFETY ENDPOINT WITH A 2.0% (4/200) RATE OF MAJOR ADVERSE EVENTS WITHIN 30 DAYS.ABRE STUDY MEETS PRIMARY SAFETY AND EFFECTIVENESS ENDPOINTS.DATA DEMONSTRATED A FREEDOM FROM CLINICALLY DRIVEN TARGET LESION REVASCULARIZATION RATE OF 92.4%.NO STENT FRACTURES AND NO DELAYED STENT MIGRATION OBSERVED WITHIN 12 MONTHS IN STUDY.

Medtronic Announces A $337 Mln Product Investment From Blackstone Life Sciences To Expand Development Of Future Diabetes Technologies

June 12 (Reuters) - Medtronic PLC <MDT.N>::MEDTRONIC ANNOUNCES A $337 MILLION PRODUCT INVESTMENT FROM BLACKSTONE LIFE SCIENCES TO EXPAND DEVELOPMENT OF FUTURE DIABETES TECHNOLOGIES.MEDTRONIC PLC - MEDTRONIC IS NOT DISCLOSING SPECIFIC DEVELOPMENT PROGRAMS.MEDTRONIC - IF SUCCESSFULLY COMMERCIALIZED, CO TO PAY ROYALTIES EXPECTED TO BE IN LOW- TO MID-SINGLE DIGIT RANGE AS % OF SALES.MEDTRONIC PLC - WILL RECEIVE UP TO $337 MILLION IN FUNDING OVER NEXT SEVERAL YEARS TO FUND FOUR IDENTIFIED DIABETES RESEARCH AND DEVELOPMENT PROGRAMS.MEDTRONIC PLC - ADDITIONAL TERMS OF ARRANGEMENT WERE NOT DISCLOSED..

Titan Medical Reports Development And License Agreements With Medtronic

June 4 (Reuters) - Titan Medical Inc <TMD.TO>::TITAN MEDICAL ANNOUNCES DEVELOPMENT AND LICENSE AGREEMENTS WITH MEDTRONIC AND SENIOR SECURED LOAN.TITAN MEDICAL - ENTERED INTO DEVELOPMENT AND LICENSE AGREEMENT WITH MEDTRONIC PLC TO FURTHER DEVELOPMENT OF ROBOTIC ASSISTED SURGICAL TECHNOLOGIES.TITAN MEDICAL - ENTERED INTO SEPARATE LICENSE AGREEMENT WITH MEDTRONIC IN RESPECT OF CERTAIN INTELLECTUAL PROPERTY OF TITAN.TITAN MEDICAL - TITAN WILL RECEIVE SERIES OF PAYMENTS TOTALING UP TO U.S. $31 MILLION FOR MEDTRONIC'S LICENSE TO ROBOTIC ASSISTED SURGICAL TECHNOLOGIES.TITAN MEDICAL - A MILESTONE OF AGREEMENT IS FOR CO TO RAISE ADDED $18 MILLION WITHIN 4 MONTHS OF DEVELOPMENT START DATE, EXPECTED TO OCCUR IN JUNE.TITAN MEDICAL - MEDTRONIC HAS LICENSED CERTAIN ROBOTIC ASSISTED SURGICAL TECHNOLOGIES FROM TITAN FOR AN UPFRONT PAYMENT OF U.S. $10 MILLION.TITAN MEDICAL - TITAN RETAINS RIGHTS TO CONTINUE TO DEVELOP AND COMMERCIALIZE CERTAIN ROBOTIC ASSISTED SURGICAL TECHNOLOGIES FOR ITS OWN BUSINESS.TITAN MEDICAL INC - CHARLES FEDERICO, WHO HAS SERVED AS CO'S CHAIRMAN SINCE MAY 2019 DECIDED TO RETIRE FROM TITAN'S BOARD.TITAN MEDICAL INC - DAVID MCNALLY, TITAN'S PRESIDENT AND CEO, HAS BEEN APPOINTED CHAIRMAN OF BOARD OF DIRECTORS.

Medtronic Reports Q4 Revenue Of $6 Bln, Hikes Qtrly Dividend To $0.58

May 21 (Reuters) - Medtronic PLC <MDT.N>::MEDTRONIC REPORTS FOURTH QUARTER AND FISCAL YEAR 2020 FINANCIAL RESULTS; ANNOUNCES DIVIDEND INCREASE.Q4 NON-GAAP EARNINGS PER SHARE $0.58.Q4 GAAP EARNINGS PER SHARE $0.48.Q4 EARNINGS PER SHARE ESTIMATE $0.68 -- REFINITIV IBES DATA.QTRLY Q4 REVENUE OF $6.0 BILLION DECREASED 26% REPORTED.QUARTERLY DIVIDEND INCREASED TO $0.58.FINANCIAL RESULTS IN-LINE WITH UPDATE PROVIDED ON APRIL 21.SPINE Q4 REVENUE OF $480 MILLION DECREASED 31 PERCENT AS REPORTED AND 32 PERCENT ON AN ORGANIC BASIS.NOT PROVIDING FORMAL ANNUAL OR QUARTERLY FINANCIAL GUIDANCE AT THIS TIME.CARDIAC AND VASCULAR GROUP Q4 REVENUE OF $2.004 BILLION DECREASED 34 PERCENT AS REPORTED AND 33 PERCENT CONSTANT CURRENCY.MEDTRONIC - REMAINS COMMITTED TO RETURNING MINIMUM OF 50% OF FREE CASH FLOW TO SHAREHOLDERS.RTG Q4 REVENUE OF $1.490 BILLION DECREASED 33 PERCENT AS REPORTED AND ON AN ORGANIC BASIS.Q4 REVENUE VIEW $6.07 BILLION -- REFINITIV IBES DATA.MINIMALLY INVASIVE THERAPIES GROUP Q4 REVENUE OF $1.934 BILLION DECREASED 14 PERCENT AS REPORTED AND 12 PERCENT CONSTANT CURRENCY.COMPANY HAS NO PUBLIC DEBT MATURING UNTIL MARCH 2021.

Medtronic Says Unit Entered Into Term Loan Agreement

May 13 (Reuters) - Medtronic PLC <MDT.N>::MEDTRONIC PLC - ON MAY 12 UNIT ENTERED INTO A TERM LOAN AGREEMENT.MEDTRONIC PLC - LOAN AGREEMENT PROVIDES FOR AN UNSECURED TERM LOAN OF UP TO JPY 300 BILLION.

Medtronic PLC - Targeting Manufacturing Of More Than 1,000 Ventilators Per Week By End Of June

Medtronic PLC <MDT.N>::MEDTRONIC PROVIDES VENTILATOR PROGRESS UPDATE.MEDTRONIC PLC - FDA AUTHORIZES USE OF PB560 IN UNITED STATES.MEDTRONIC PLC - COMPANY LAUNCHES PB980 REMOTE CAPABILITIES.MEDTRONIC PLC - MEDTRONIC EXPECTS FIVE-FOLD INCREASE IN ITS VENTILATOR PRODUCTION BY END OF JUNE.MEDTRONIC PLC - PURITAN BENNETT 560 (PB560) VENTILATOR WILL SOON BE AVAILABLE IN UNITED STATES.MEDTRONIC PLC - COMPANY EXPECTS PB560 WILL BE AVAILABLE IN U.S. IN MAY..MEDTRONIC PLC - PB560 VENTILATOR AVERAGE SELLING PRICE IS UNDER $10,000 USD..MEDTRONIC PLC - CURRENTLY IN LIMITED MARKET RELEASE OF A NEW REMOTE MANAGEMENT CAPABILITY FOR ITS PURITAN BENNETT 980 VENTILATOR WITH TWO HOSPITALS.MEDTRONIC PLC - MEDTRONIC SHIPS MORE THAN 300 VENTILATORS PER WEEK TO CUSTOMERS.MEDTRONIC PLC - MEDTRONIC IS PRIORITIZING PB980 AND PB560 PRODUCTION.MEDTRONIC PLC - BY END OF APRIL, MEDTRONIC EXPECTS TO MANUFACTURE MORE THAN 400 VENTILATORS PER WEEK..MEDTRONIC PLC - BY END OF MAY, COMPANY IS EXPECTING TO MANUFACTURE MORE THAN 700 VENTILATORS PER WEEK.MEDTRONIC PLC - TARGETING MANUFACTURING OF MORE THAN 1,000 VENTILATORS PER WEEK BY END OF JUNE.

FDA Says Medtronic Recalls Pipeline Flex Embolization Devices Due To Risk Of Device Fracture

March 30 (Reuters) - U.S. FDA::FDA- MEDTRONIC RECALLS PIPELINE FLEX EMBOLIZATION DEVICES DUE TO RISK OF DEVICE FRACTURE.FDA- IDENTIFIED MEDTRONIC'S RECALL OF PIPELINE FLEX EMBOLIZATION DEVICES AS CLASS I RECALL.FDA- MEDTRONIC RECALLED 822 PIPELINE FLEX EMBOLIZATION DEVICES IN THE U.S..FDA- GOT 50 MEDICAL DEVICE REPORTS, WITH 10 INJURIES, 1 DEATH, FROM NOV 1, TO MAR 1, RELATED TO MEDTRONIC'S RECALLED PIPELINE FLEX EMBOLIZATION DEVICES.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up